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ABSTRACT
Epstein-Barr Virus (EBV) is a gammaherpesvirus that infects the majority of the human population and is linked to the develop-
ment of multiple cancers, including nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is considered the primary
oncoprotein of EBV, and in epithelial cells it induces the expression and activation, or phosphorylation, of the epidermal growth
factor receptor kinase. To identify effects on additional kinases, an unbiased screen of receptor tyrosine kinases potentially acti-
vated by LMP1 was performed. Using a protein array, it was determined that LMP1 selectively activates insulin-like growth fac-
tor 1 receptor (IGF1R). This activation takes place in fibroblast, epithelial, and nasopharyngeal cell lines that express LMP1 sta-
bly and transiently. Of note, LMP1 altered the phosphorylation, but not the expression, of IGF1R. The use of LMP1 mutants with
defective signaling domains revealed that the C-terminal activating region 2 domain of LMP1 increased the mRNA expression
and the secretion of the ligand IGF1, which promoted phosphorylation of IGF1R. IGF1R phosphorylation was dependent upon
activation of canonical NF-B signaling and was suppressed by IB and a dominant negative form of TRAF6. Inhibition of
IGF1R activation with two small-molecule inhibitors, AG1024 and picropodophyllin (PPP), or with short hairpin RNA (shRNA)
directed against IGF1R selectively reduced proliferation, focus formation, and Akt activation in LMP1-positive cells but did not
impair LMP1-induced cell migration. Expression of constitutively active Akt rescued cell proliferation in the presence of IGF1R
inhibitors. These findings suggest that LMP1-mediated activation of IGF1R contributes to the ability of LMP1 to transform epi-
thelial cells.
IMPORTANCE
EBV is linked to the development of multiple cancers in both lymphoid and epithelial cells, including nasopharyngeal carci-
noma. Nasopharyngeal carcinoma is a major cancer that develops in specific populations, with nearly 80,000 new cases reported
annually. LMP1 is consistently expressed in early lesions and continues to be detected within 50 to 80% of these cancers at later
stages. It is therefore of paramount importance to understand the mechanisms through which LMP1 alters cell growth and con-
tributes to tumorigenesis. This study is the first to determine that LMP1 activates the IGF1R tyrosine kinase by regulating ex-
pression of the ligand IGF1. Additionally, the data in this paper reveal that specific targeting of IGF1R selectively impacts LMP1-
positive cells. These findings suggest that therapies directed against IGF1R may specifically impair the growth of EBV-infected
cells.
Epstein-Barr Virus (EBV) is a gammaherpesvirus transmittedthrough bodily fluids that infects both lymphocytes and oro-
pharyngeal epithelial cells. It is estimated that greater than 90% of
the human population are EBV carriers, and EBV infection is an
etiological factor in the development of multiple cancers such as
Burkitt lymphoma, Hodgkin lymphoma, gastric carcinoma, and
nasopharyngeal carcinoma (NPC) (1). Roughly 78,000 new cases
of NPC are reported each year, and there is a great need to develop
improved treatments with increased specificity for malignant
NPC cells (2).
Latent membrane protein 1 (LMP1) is considered the primary
oncoprotein of EBV, and it consists of a short intracellular amino
terminus, six transmembrane domains, and an intracellular car-
boxy-terminal tail containing 3 C-terminal activating regions
(CTARs) that serve as docking sites for tumor necrosis factor re-
ceptor (TNF)-associated factors (TRAFs). The transmembrane
domains of LMP1 promote protein aggregation and cytoskeletal
remodeling, resulting in constitutive LMP1 activation and signal-
ing. LMP1 is considered a viral mimetic of the tumor necrosis
factor receptor (TNFR) CD40, and it activates multiple signaling
pathways, including NF-B, AKT, and mitogen-activated protein
kinase (MAPK) signaling (1, 3) Specifically, CTAR1 binds TRAF1,
-2, -3, and -5 and enhances AKT and MAPK signaling to promote
rodent fibroblast transformation (4, 5). CTAR2 binds the TNF
receptor-associated death domain protein (TRADD) and the TNF
receptor-interacting protein (RIP) (1, 6).
Both CTAR1 and CTAR2 modulate cellular transcription via
NF-B signaling (7). Canonical NF-B signaling, which is regu-
lated by the inhibitor of NF-B alpha (IB), is activated primar-
ily by CTAR2, although CTAR1 may also promote canonical sig-
naling (3, 7, 8). CTAR2 activates canonical NF-B signaling
through TRAF6, which binds CTAR2 indirectly via intermediates
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such as TRADD or RIP (9). In contrast, only CTAR1 can activate
noncanonical NF-B signaling through p100 and RelB, and LMP1
greatly increases the processing of p100 to p52 (8, 10–12). Many of
the LMP1-associated TRAFs are ubiquitin ligases, which likely
enables LMP1 effects on protein stability and localization (13).
Expression of LMP1 is particularly prevalent in NPC, where it
is detected in 50 to 80% of tumors (14). LMP1 promotes epithelial
cell survival and motility, and expression of LMP1 clinically cor-
relates with NPC metastasis (1, 14). One contributing factor to
cellular transformation is the ability of LMP1 to induce the ex-
pression and constitutive phosphorylation of the receptor ty-
rosine kinase (RTK) epidermal growth factor receptor (EGFR)
(15). In epithelial cells, the CTAR1 domain of LMP1 signals
through protein kinase C  (PKC) and STAT3 to induce EGFR
expression via a unique form of NF-B signaling wherein p50
dimers bind to BCL3 to regulate gene transcription (10, 16–18).
Although LMP1 increases the transcription of the EGFR ligand,
transforming growth factor- (TGF-), TGF- does not appear
to be necessary for EGFR phosphorylation (19). Hence, it is un-
clear how LMP1 regulates EGFR activation.
EGFR is one of 58 human RTKs, which are divided into 20
families based on structural motifs and the similarities of their
kinase domains (20). Broadly speaking, RTKs exist as transmem-
brane receptors which undergo dimerization and cross-phos-
phorylation upon ligand binding to enable downstream signaling.
Murine models of NPC have determined that targeting EGFR de-
creases tumor growth and invasion (21, 22). Analysis of other
cancer subtypes has revealed that tumors quickly develop resis-
tance to EGFR monotherapy, but it may be possible to overcome
this resistance using therapies that target multiple RTKs simulta-
neously (23–25). Collectively, these data suggest that targeting
RTKs such as EGFR may provide novel mechanisms for treating
NPC, either as individual therapeutics or in combination with
EGFR inhibitors. Recent studies have suggested that LMP1 may
regulate the expression of RTKs such as RON, but an unbiased
screen of RTKs activated by LMP1 has yet to be performed (26,
27). The activation of 49 different RTKs was therefore analyzed in
the presence and absence of LMP1. The resulting data indicate a
novel mechanism by which LMP1 may transform cells and offer
the opportunity to develop new therapies for the selective treat-
ment of LMP1-positive NPC.
MATERIALS AND METHODS
Cell lines, C15 tumors, plasmid constructs, and small-molecule inhib-
itors. Rat1 and 293T cells were cultured in Dulbecco modified Eagle me-
dium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Gibco,
NY, USA) and 1% penicillin-streptomycin. MCF10a cells were cultured in
DMEM-F12 (Gibco) with 5% horse serum, 1% penicillin-streptomycin,
0.5 g/ml hydrocortisone, 100 ng/ml cholera toxin, 10 g/ml insulin, and
20 ng/ml EGF. NP69 cells were grown in keratinocyte serum-free medium
supplemented with 5% FBS, 1% penicillin-streptomycin, 25 g/ml bo-
vine pituitary extract, and 0.2 ng/ml EGF. C666 cells were grown on fi-
bronectin-coated plates with RPMI (Gibco) supplemented with 10% FBS
and 1% penicillin-streptomycin. C15 tumors were passaged serially in
nude mice. Tumors were dissected and incubated with NP-40 lysis buffer
(1% NP-40, 150 nM NaCl, 50 mM Tris [pH 7.4], 5 mM EDTA, and 10%
glycerol) for 1 h. Remaining tissue debris was spun down and extracted,
while the supernatant was kept for immunoblotting analysis. Cells were
also lysed in NP-40 lysis buffer. Protease and phosphatase inhibitors (Sig-
ma-Aldrich, MO, USA) were added to NP-40 lysis buffer before each use.
LMP1 constructs containing hemagglutinin (HA)-tagged wild-type
(WT) LMP1, LMP1 A5, or LMP1 378 in the pBabe-puro backbone
have been described previously (5). A pLKO.1 plasmid containing
scrambled short hairpin RNA (shRNA) (plasmid 1864) and a pLNCX
plasmid containing myristoylated Akt (myr-Akt) (plasmid 9005) were
obtained from Addgene (MA, USA) (28, 29). pLKO.1 plasmids with
shRNA directed against IGF1R (shIGF-1, TRCN0000121297; shIGF-2,
TRCN0000121301) were obtained from the Lenti-shRNA Core Facil-
ity at the University of North Carolina, Chapel Hill (NC, USA). The
superrepressor (SR) IB construct in the pcDNA3-zeo backbone was
made as described previously (30). A dominant negative TRAF6 (dn-
TRAF6) construct and a Myc-tagged dominant negative TRAF2 con-
struct, both in the pBabe-puro backbone, were made as described
previously (5, 31, 32). Prior to transfection, cells were seeded to 50%
confluence in a 10-cm tissue culture dish. Cells were transfected with 6
g of DNA and 10 l Lipofectamine 2000 (Invitrogen, NY, USA)
for 5 h.
The small-molecule inhibitor picropodophyllin (PPP) was purchased
from Santa Cruz Biotechnology (TX, USA), and AG1024 was obtained
from SelleckChem (TX, USA). Both inhibitors were reconstituted in di-
methyl sulfoxide (DMSO). Where indicated, cells were treated with
DMSO as a vehicle control. The DMSO vehicle control was always used at
a concentration equal to the highest concentration of experimental inhib-
itors (usually equivalent to 20 M AG1024).
Immunoprecipitation, immunoblotting, antibodies, and RTK ar-
rays. Immunoprecipitations to detect phospho-IGF1R expression were
conducted using 1 mg of protein harvested 2 days after transfection. Ly-
sates were either immunoprecipitated with anti-IGF1R (Santa Cruz Bio-
technology) and probed with antiphosphotyrosine (anti-pTyr) (Cell Sig-
naling Technology, MA, USA) or immunoprecipitated with anti-pTyr
and probed with anti-IGF1R (Cell Signaling Technology). Where indi-
cated, IgG (Jackson ImmunoResearch, PA, USA) was used to immuno-
precipitate lysates as a negative control. Other antibodies used for immu-
noblotting included anti-LMP1 CS1-4 (Dako, CA, USA); anti-HA
(Covance, NC, USA); anti-GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase), anti-IB, anti-Myc, and anti-TRAF6 (Santa Cruz Biotech-
nology); and anti-phospho-Akt and anti-Akt (Cell Signaling Technol-
ogy). Immunoblotting was conducted as described previously (33).
Briefly, protein samples (either immunoprecipitations or 25 g of total
cell lysates as determined by the Bradford assay) in Laemmli loading buf-
fer were loaded onto a 12% agarose SDS-polyacrylamide gel. Gels were
transferred onto polyvinylidene difluoride (PVDF) membranes (Fisher
Scientific, PA, USA) prior to antibody analysis.
A neutralizing anti-IGF1R was obtained from R&D Systems (MN,
USA). The neutralizing anti-IGF1R was used in cell medium diluted 1:2
with Opti-MEM (Gibco). Where indicated, cells were treated with control
goat IgG (Jackson ImmunoResearch) instead of neutralizing anti-IGF1R.
The control IgG was used at concentrations equal to the highest dose of
anti-IGF1R (usually 8 g/ml).
The relative intensities of bands in immunoblots were assessed with
ImageJ software (34). To determine LMP1 expression in cell lines relative
to C15 tumors, LMP1 expression was normalized to GAPDH bands for a
given sample. The normalized LMP1 expression in cell lines was then
divided by the average normalized LMP1 expression in C15 xenografts.
To quantitate Akt phosphorylation, the amount of phospho-Akt was nor-
malized to GAPDH bands. Relative Akt phosphorylation was determined
by dividing the normalized Akt phosphorylation for every experimental
treatment by the normalized Akt phosphorylation for untreated cells. The
fraction of relative Akt phosphorylation for LMP1-positive cells was then
divided by the fraction of relative Akt phosphorylation for pBabe vector
control cells. RTK phosphoarrays were purchased from R&D Systems and
were used with 500 g of protein in accordance with the manufacturer’s
instructions. A detailed list of RTKs examined in the array may be found at
http://www.rndsystems.com/Products/ARY001B.
Proliferation and focus formation assays. Cell proliferation was as-
sessed using a variant of the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
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carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay called
the CellTiter 96 aqueous one-solution cell proliferation assay (Promega,
WI, USA) in accordance with the manufacturer’s instructions. Briefly,
1,000 cells were seeded in 96-well plates. Cells treated with shRNA con-
structs were seeded 1 day after transfection. After 4 h, a T0 time point was
read to assess cell seeding, and the indicated treatments (small-molecule
inhibitors or neutralizing anti-IGF1R) were added. The cell number was
assessed again 48 h later, and the ratio of the number at T48 to that at T0
was obtained. For pBabe- or LMP1-positive cells, the proliferation of
treated cells was taken as a fraction of the proliferation of untreated cells.
The proliferating fraction of LMP1-positive cells was then divided by the
proliferating fraction of pBabe vector control cells.
Focus formation was assessed by seeding 500 cells in 6-well dishes and
allowing them to grow for 10 days before staining with Coomassie dye. As
with proliferation assays, cells transfected with shRNA were seeded 1 day
after transfection. Cells were treated with small-molecule inhibitors start-
ing 4 h after seeding and throughout the remainder of the experiment.
Focus number and size were quantitated with ImageJ software (34).
Where indicated, the focus number or size of treated cells was taken as a
fraction of the focus size or number of untreated cells. The fraction of
LMP1-positive foci was then taken relative to the fraction of pBabe foci.
Migration assays. Cell migration was measured using 8-m 24-well
transwell assays from BD Bioscience (CA, USA). Briefly, 20,000 Rat1 cells
in 0.1% FBS were seeded in the top chamber and allowed to migrate
toward 10% FBS in the bottom chamber for 6 h. Where indicated, the
small-molecule inhibitors PPP and AG1024 were placed in both the top
and bottom chambers at the time of cell seeding. Cells that did not migrate
through the transwell were scraped off, while migrating cells were stained.
Four random fields were counted for each transwell to determine the
number of migrating cells. Where indicated, the number of treated mi-
grating cells was assessed as a fraction of the number of untreated migrat-
ing cells. The fraction of migrating LMP1-positive cells was then taken
relative to the fraction of migratory pBabe vector control cells.
qRT-PCR. RNA was harvested from cells using the RNeasy Plus mini-
kit from Qiagen (CA, USA). Quantitative real-time PCR (qRT-PCR) was
performed using 100 ng of RNA and the QuantiFast SYBR green RT-PCR
kit from Qiagen according to the manufacturer’s instructions. Primers
were designed using Primer-BLAST and were ordered from Eurofins
Genomics (AL, USA). Primers used were as follows: IGF1R-F, GAG TGG
AGA AAT CTG CGG GC; IGF1R-R, TCG ATC AGG GTG CAG TTC TC;
GAPDH-F, TGC ACC ACC AAC TGC TTA GC; GAPDH-R, GAG GGG
CCA TCC ACA GTC TT; IGF1-F, AAT CAG CAG TCT TCC AAC CCA;
IGF1-R, CAC AGC GCC AGG TAG AAG AG; IGF2-F, CCC GTC GCA
CAT TCG GC; IGF2-R, GGG ATT CCC ATT GGT GTC TGG A; LMP1-F,
CAT AGC CCT AGC GAC TCT GC; and LMP1-R, AAA GGG CTC CAA
GTG GAC AG.
ELISA. The IGF1 Quantikine enzyme-linked immunosorbent assay
(ELISA) kit was obtained from R&D Systems and used in accordance with
the manufacturer’s instructions. Briefly, 50,000 cells were seeded in 6-well
dishes and allowed to grow for 3 days. Cell medium was harvested, and 2
l of medium was used in the ELISA. Readings from “control” medium
without cells were subtracted from experimental medium readouts.
Where indicated, the relative IGF1 concentration of LMP1-positive cells
was divided by the IGF1 concentration of pBabe control cells.
RESULTS
LMP1 expression increases IGF1R activation. Constructs con-
taining LMP1 or pBabe empty vector control were expressed in
multiple cell lines (Fig. 1A). LMP1 was transiently transfected into
293T embryonic kidney cells, C666 nasopharyngeal carcinoma
cells, and NP69 premalignant nasopharyngeal epithelial cells.
LMP1 was stably expressed in immortalized, nontransformed
MCF10a epithelial cells and Rat1 rodent fibroblasts (Fig. 1A). To
confirm that the transfected cell lines expressed LMP1 at physio-
logically relevant levels, the expression of LMP1 in transfected
cells was compared to LMP1 expression in C15 xenograft tumors.
C15 tumors are serially passaged in vivo models of NPC that con-
tain the EBV genome and consistently express LMP1 (35) (Fig.
1B). Immunoblots were used to analyze LMP1 expression in 3
samples of each cell line with and without LMP1 transfection and
in lysates from C15 tumors. LMP1 expression was normalized to
GAPDH for each sample, and the ratio of LMP1 expression was
then taken relative to the average LMP1 expression in C15 tumors
for each cell line (Fig. 1B). LMP1 expression was not detected in
parental 293T, Rat1, NP69, or MCF10a cells (data not shown). In
contrast, the C666 cell line contains the EBV genome and is
thought to express LMP1 at low levels (33, 36). Parental C666 cells
expressed approximately 20% as much LMP1 as C15 tumors (Fig.
1B). As expected, transfection increased LMP1 expression in all
cell lines. Importantly, transfected cell lines expressed an amount
of LMP1 similar to that for C15 tumors (average range, 60 to
150% of LMP1 found in C15 tumors), indicating that the cell
lines were expressing LMP1 at physiologically relevant levels
(Fig. 1B).
Two days after transfection, lysates from 293T cells expressing
LMP1 or pBabe were incubated with protein arrays that were
spotted in duplicate with antibodies against 49 distinct RTKs.
Arrays were probed with antiphosphotyrosine (anti-pTyr) to
determine which RTKs were specifically activated in the pres-
ence of LMP1 (Fig. 1C). On the array, darker spots were indic-
ative of higher levels of phosphorylation, and positive controls
were spotted in the upper left, upper right, and lower right
corners, while the lower left corner served as a negative control.
RTKs that were clearly phosphorylated were identified and la-
beled (Fig. 1C).
In keeping with previous reports, expression of LMP1 in-
creased the phosphorylation of EGFR (15–17). At the same time,
LMP1 decreased the activation of AXL and increased the phos-
phorylation of insulin-like growth factor 1 receptor (IGF1R). In-
terestingly, activation of insulin receptor (IR), which is closely
related to IGF1R, was not altered by LMP1 (Fig. 1C). IGF1R is a
tetrameric RTK implicated in the development of multiple cancer
subtypes, and its signaling capabilities and role in cellular trans-
formation have been extensively reviewed elsewhere (37, 38). Ma-
ture IGF1R contains two extracellular alpha subunits linked by
disulfide bonds and two membrane-spanning beta subunits that
contain intracellular kinase domains and docking sites for adaptor
proteins. The alpha subunits of IGF1R have a molecular mass of
roughly 130 kDa, while the beta subunits have a molecular mass of
approximately 97 kDa and frequently generate the predominant
bands detected via immunoblotting (38). Most antibodies that
detect phospho-IGF1R (pIGF1R) also cross-react with pIR. To
recapitulate the detection method in the protein arrays, cell lysates
were immunoprecipitated with anti-IGF1R and probed with anti-
pTyr to specifically detect pIGF1R. This approach demonstrated
that LMP1 increased the activation of IGF1R in 293T, C666,
NP69, MCF10a, and Rat1 cells (Fig. 1D). The C666 cell line con-
tains the EBV genome and is thought to express LMP2 and EBV
RNAs, with trace levels of LMP1 (33, 36). Expression of exogenous
LMP1 in C666 cells induced IGF1R activation in the presence of
the EBV genome, indicating that LMP1 can regulate pIGF1R levels
in the context of EBV infection. Elevated pIGF1R was detected in
cell lines stably (MCF10a and Rat1) and transiently (293T, C666,
and NP69) expressing LMP1, indicating that the effects of LMP1
on IGF1R are consistent (Fig. 1D).
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Inhibiting IGF1R reduces cell proliferation, focus forma-
tion, and Akt phosphorylation but does not influence cell mi-
gration. The small-molecule inhibitors AG1024 and picropodo-
phyllin (PPP) are designed to inhibit IGF1R phosphorylation,
with 50% inhibitory concentration (IC50) values of 7 M and 40
to 70 nM, respectively (39–42). Cells treated with AG1024 or PPP
were immunoprecipitated with anti-pTyr and immunoblotted
with anti-IGF1R. This approach provided a more sensitive mech-
anism to detect pIGF1R while reinforcing the results obtained
from reciprocal immunoprecipitations used for Fig. 1D. As ex-
pected, AG1024 and PPP reduced LMP1-induced IGF1R activa-
tion in a dose-dependent manner but did not alter IGF1R or
LMP1 expression (Fig. 2A). PPP inhibited IGF1R phosphoryla-
tion with an IC50 roughly equal to 50 nM, which is in agreement
with prior results (39). Although AG1024 reduced IGF1R phos-
phorylation, its IC50 was approximately 20 M (Fig. 2A). Previous
studies have, however, determined that AG1024 targets IR with an
IC50 of roughly 57 M (40). Since IR is the RTK most closely
related to IGF1R, it is possible that AG1024 is still selectively tar-
geting IGF1R at doses of 20 M (40). Both PPP and AG1024 were
subsequently used in parallel to ensure that experimental obser-
vations were not skewed by off-target effects of the small-molecule
inhibitors.
Compared to pBabe vector control cells, expression of LMP1
increased the proliferation of 293T and MCF10a cells by approx-
imately 50% as measured by MTS assay (Fig. 2B). To take this
fundamental proliferation difference into account, the prolifera-
tion of cells treated with AG1024 or PPP was normalized to the
proliferation of untreated cells. These calculations enabled direct
comparison of the amount of proliferating LMP1-positive cells
and the amount of proliferating pBabe vector control cells. The
fraction of LMP1-positive proliferating cells was then calculated
relative to the fraction of proliferating pBabe control cells. Treat-
ment with AG1024 or PPP selectively reduced the proliferation of
LMP1-positive cells, although PPP decreased cell proliferation
more effectively than AG1024 (Fig. 2C and D). Recent studies as
well as unpublished data from our lab indicate that expression of
LMP1 can alter the metabolism of cells, which may affect the re-
sults of traditional proliferation assays that measure levels of met-
abolic by-products (43). Focus formation assays were therefore
used to simultaneously assess loss of contact inhibition and cell
growth independently of metabolic by-products. Briefly, a small
number of cells were seeded and allowed to grow for 10 days. Both
the size and number of resulting colonies are indicative of cell
proliferation, while the size of the colonies also correlates with loss
of contact inhibition. In this way, two hallmarks of cancer devel-
FIG 1 LMP1 increases IGF1R activation. (A) Immunoblots for LMP1 expression in transiently transfected cell lines (293T, C666, and NP69) and in stably
transfected cell lines (MCF10a and Rat1). (B) Immunoblots were run to examine LMP1 expression in the following cell lines with (LMP1) or without LMP1
transfection: 293T (2)  LMP1, Rat1 (R)  LMP1, MCF10a (M)  LMP1, NP69 (N)  LMP1, C666 (C), and C666 (C)  LMP1. Three samples were examined,
and expression of LMP1 was calculated relative to LMP1 expression in C15 xenograft tumors. Average LMP1 expression is depicted. (C) 293T lysates expressing
LMP1 or pBabe empty vector were added to arrays spotted in duplicate with antibodies against 49 human RTKs. Arrays were probed with anti-pTyr to detect
specific RTK phosphorylation; darker spots indicate stronger activation. Spots in the upper left, upper right, and lower right are positive controls, while that in
the lower left is a negative control. (D) The indicated cells were lysed and immunoprecipitated with anti-IGF1R or IgG. The resulting immunoprecipitates were
probed with anti-pTyr or with anti-IGF1R. Beta chains of IGF1R are 97 kDa (arrows), and alpha chains of IGF1R are 130 kDa.
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FIG 2 LMP1 promotes cell proliferation and focus formation via IGF1R. (A) LMP1-expressing 293T cells were incubated with the indicated micromolar
concentrations of AG1024 (AG) or PPP (P) for 1 day. Cell lysates were immunoprecipitated (IP) with anti-pTyr and probed with anti-IGF1R to specifically detect
phospho-IGF1R. Numerical values indicate fold reduction in pIGF1R compared to that in a dimethyl sulfoxide (DMSO) vehicle control. In parallel, total cell
lysates (TCLs) were probed for IGF1R, LMP1, and GAPDH. (B to D) MTS assays were used to assess the proliferation of LMP1-positive cells relative to pBabe cell
proliferation over a 2-day period (B). In the same time span, cells were exposed to DMSO vehicle control, AG1024 (C), or PPP (D), and proliferation was
measured. (E to H) MCF10a cells were sparsely seeded and given the indicated treatment for 10 days before foci were stained and quantitated (E). The focus
number and size of LMP1-expressing cells were calculated relative to those for pBabe vector controls (F). Four hours after seeding, cells were treated with AG1024
or PPP, and the relative number (G) and size (H) of foci were subsequently assessed. In panels C, D, G, and H, the fraction of treated cell growth or focus
formation was calculated relative to that for untreated cells. The proportion of LMP1-positive cells was then calculated relative to that for pBabe vector control
cells. All drug doses are micromolar. *, LMP1-positive cells are significantly different than pBabe cells (P  0.05).
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opment may be assessed concurrently. As expected, LMP1 dra-
matically increased the size and number of foci formed in 293T,
MCF10a, and Rat1 cells (Fig. 2E and F). Inhibition of IGF1R se-
lectively decreased the size and number of foci formed by LMP1-
positive cells relative to those formed by vector control cells (Fig.
2G and H). Both focus size and focus number were reduced by
IGF1R inhibitors in a dose-dependent manner, indicating that
pIGF1R selectively promoted focus development in all LMP1-
positive cells (Fig. 2G and H).
LMP1 is capable of increasing cell motility and promoting me-
tastasis (5, 44). In agreement with these observations, LMP1 ex-
pression increased Rat1 cell migration by roughly 3-fold com-
pared to pBabe vector control cells in a transwell assay (Fig. 3A).
Treatment with AG1024 or PPP did not inhibit the migration of
LMP1-expressing cells relative to that of vector control cells (Fig.
3B). Thus, IGF1R signaling does not appear to regulate LMP1-
induced migration in rodent fibroblasts.
Upon activation, the intracellular domains of IGF1R become
cross-phosphorylated and serve as docking sites for adaptor pro-
teins such as insulin receptor substrates (IRSs) or Shc. Although
IGF1R can activate multiple downstream signaling pathways, it is
traditionally associated with Akt signaling, and it has been shown
that phosphatidylinositol 3-kinase (PI3K) can interact with either
IRSs or IGF1R itself to induce Akt phosphorylation (37). In the
presence of serum, expression of LMP1 did not significantly affect
pAkt levels; however, treatment with AG1024 or PPP selectively
reduced Akt phosphorylation in LMP1-positive cells relative to
that in LMP1-negative cells (Fig. 3C to E and data not shown).
These data indicate that LMP1 expression promotes Akt phos-
phorylation through IGF1R activation, while pBabe control cells
activate Akt phosphorylation via a different mechanism.
To determine whether IGF1R regulated cell proliferation via
pAkt, a myristoylated Akt (myr-Akt) construct was transfected
into LMP1-expressing 293T and MCF10a cells (Fig. 3F). The my-
ristoylation targets Akt to the plasma membrane, allowing Akt to
become constitutively active (29). The presence of myr-Akt pre-
vented PPP from selectively decreasing the proliferation of LMP1-
expressing cells, suggesting that the loss of Akt phosphorylation
generated by targeting IGF1R regulates the observed changes in
cell proliferation (Fig. 3G).
Effects of small-molecule IGF1R inhibitors are recapitulated
by shRNA. As mentioned above, AG1024 and PPP are small-mol-
ecule inhibitors designed to prevent IGF1R activation. Although
AG1024 and PPP are thought to specifically inhibit IGF1R, it is
possible that these small-molecule inhibitors may have other, off-
target effects. To verify that LMP1 specifically regulates cell pro-
liferation and Akt activation via IGF1R, two different shRNAs
(shIGF-1/2) were used to knock down expression of IGF1R. These
shRNAs reduced IGF1R expression compared to that in scram-
bled shRNA control cells or untreated cells and did not affect
LMP1 expression (Fig. 4A). IGF1R knockdown was effective in
both LMP1-expressing and pBabe vector control cells, yet target-
ing IGF1R selectively reduced Akt phosphorylation in LMP1-pos-
itive cells compared to LMP1-negative cells (Fig. 4A and B). Due
to measurement variability, the decrease in Akt activation in
LMP1-expressing cells was not significant compared to activation
in vector control cells (Fig. 4B). Proliferation of LMP1-positive
cells was selectively and significantly decreased by IGF1R knock-
down relative to that of vector control cells (Fig. 4C). Importantly,
the degree to which IGF1R knockdown impacted Akt phosphor-
ylation paralleled the decrease in cell proliferation, suggesting that
IGF1R regulates cell proliferation through Akt activation (Fig. 4B
and C). In agreement with previous results, LMP1 expression in-
creased the size and number of foci formed relative to those in
pBabe control cells, and these effects were specifically abrogated
by loss of IGF1R expression (Fig. 4D to F).
LMP1 mediates IGF1R activation via ligand IGF1. Activating
IGF1R mutations in cancer have not yet been identified. Instead,
IGF1R may be activated by overexpression or by ligands such as
IGF1 or IGF2. In many cancer subtypes, cells promote IGF1R
activation by secreting ligands in an autocrine manner (37). SYBR
green qRT-PCR was used to compare the expression of mRNA in
LMP1-positive cells to mRNA expression in pBabe control cells.
These data revealed that LMP1 expression did not alter the expres-
sion of the IGF1R or IGF2 gene relative to that in pBabe vector
control cells (Fig. 5A). In contrast, mRNA of IGF1 was elevated by
roughly 2-fold in LMP1-positive cells compared to LMP1-nega-
tive cells (Fig. 5A). ELISAs verified that increased mRNA levels of
IGF1 correlated with elevated secretion of IGF1 in LMP1-positive
cells relative to vector control cells (Fig. 5B). The agreement be-
tween the ELISAs and the qRT-PCR data suggests that LMP1 reg-
ulates IGF1 secretion via de novo synthesis of the growth factor
(Fig. 5A and B). To verify that LMP1 regulated IGF1R activation
via ligand secretion, a neutralizing anti-IGF1R was used to prevent
ligand binding. As a control, cells were also treated with goat IgG
to verify the specificity of the effects induced by anti-IGF1R. In-
cubation with increasing concentrations of anti-IGF1R over a 24-
hour period reduced IGF1R tyrosine phosphorylation in LMP1-
positive cells, while incubation with IgG controls did not alter
pIGF1R levels (Fig. 5C). Neither the neutralizing antibody nor the
IgG control altered expression of IGF1R or LMP1 (Fig. 5C). Use of
IgG controls did not alter the proliferation of LMP1-positive 293T
or MCF10a cells relative to that of pBabe vector control cells (Fig.
5D). Neutralizing anti-IGF1R, however, selectively decreased the
proliferation of LMP1-expressing cells relative to that of LMP1-
negative cells (Fig. 5D).
The CTAR2 domain of LMP1 regulates IGF1R activation.
LMP1 contains 2 CTAR domains (CTAR1 and -2) that regulate
the majority of LMP1-mediated signaling. LMP1 mutants without
a functional CTAR1 or CTAR2 domain have been previously de-
scribed (5). Briefly, the functionality of CTAR1 was disrupted by
mutating the TRAF-binding PQQAT region to AAAAA to gener-
ate the A5 LMP1 mutant. CTAR2 was deleted from LMP1 by
truncating the protein at amino acid 378 to generate the 378 LMP1
mutant (5). Both the A5 and the 378 LMP1 mutants are HA
tagged, and the deletion within the 378 mutant makes it slightly
smaller than the predicted 66-kDa LMP1 (Fig. 6A). The wild-type
(WT) LMP1 construct was tagged with both FLAG and HA, which
increased the molecular mass of WT LMP1 to slightly above the
predicted 66-kDa mass (Fig. 6A). Transfection of the LMP1 con-
structs or pBabe control vectors into cells did not alter the expres-
sion of IGF1R at the protein level (Fig. 6A). In contrast, LMP1 378
selectively reduced pIGF1R levels compared to WT LMP1 or
LMP1 A5 (Fig. 6B). Additionally, SYBR green qRT-PCR demon-
strated that LMP1 378 decreased the mRNA levels of IGF1R ligand
IGF1 (Fig. 6C). In keeping with previous findings, ELISAs con-
firmed that WT LMP1 and LMP1 A5 significantly increased IGF1
secretion relative to that for pBabe controls, and LMP1 378 signif-
icantly reduced the secretion of IGF1 relative to that for WT LMP1
(Fig. 6D). Interestingly, LMP1 A5 also slightly reduced the mRNA
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FIG 3 Inhibiting IGF1R reduces Akt phosphorylation but does not alter LMP1-mediated migration. (A) The number of cells that migrated through a transwell
system over a 6-h span was assessed for Rat1 cells expressing LMP1 or pBabe vector control. (B) Rat1 cells were treated with DMSO vehicle control, AG1024, or
PPP and allowed to migrate through a transwell system. The migration of LMP1-positive cells is shown relative to that of pBabe control cells. (C to E) In MCF10a
cells, immunoblots were used to assess the activation of Akt after AG1024 or PPP treatment for 1 day (C). The activation of Akt relative to GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase) was calculated for AG1024 (D) and PPP (E). The fraction of Akt activation in treated cells was taken relative to that in
untreated cells. Ratios of Akt activation in LMP1-positive cells relative to that in LMP1-negative cells were then calculated. (F) Immunoblots for expression of
myr-Akt (Akt) in LMP1-expressing 293T and MCF10a cells. (G) The MTS assay was used to assess cell proliferation of 293T (2) and MCF10a (M) cells in the
presence of the indicated micromolar doses of PPP. Proliferation of LMP1 cells with or without myr-Akt is depicted relative to that of vector control cells. *,
LMP1-positive cells were significantly different than vector control cells (P  0.05).
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expression and secretion of IGF1 compared to that for WT LMP1,
but LMP1 A5 did not impact IGF1 to the same extent as LMP1 378
(Fig. 6C and D).
TRAF2 is essential for CTAR1-mediated activation of NF-B
signaling, while TRAF6 is a crucial intermediate regulating the
ability of CTAR2 to activate the canonical NF-B pathway (3, 8, 9,
45). It was therefore hypothesized that canonical TRAF6-medi-
ated NF-B signaling would be required for LMP1 to activate
FIG 4 The use of shRNA verifies that targeting IGF1R specifically reduces Akt activation, cell proliferation, and focus formation in LMP1-positive cells. (A and
B) Two different shRNAs (shIGF-1 and shIGF-2) were used to knock down IGF1R in MCF10a cells expressing LMP1 or pBabe. Scrambled shRNA (sc) was used
as a control. Activation of Akt was subsequently assessed (A). The fraction of Akt activation relative to a GAPDH loading control in LMP1-expressing cells was
determined relative to LMP1-negative cells (B). (C) MTS assays measured cell proliferation of LMP1-positive cells compared to pBabe cells after the indicated
treatment. (D to F) After transfection with shRNA or sc, 293T cells were sparsely seeded and allowed to form foci for 10 days (D). The relative number (E) and
size (F) of foci were then calculated for LMP1-expressing cells relative to pBabe cells. In panels B, C, E, and F the fraction of treated cell growth or focus formation
was calculated relative to that for untreated cells. The proportion of LMP1-positive cells was then calculated relative to that for pBabe vector control cells. *,
LMP1-positive cells were significantly different than pBabe control cells (P  0.05).
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IGF1R. To test this theory, an IB superrepressor (SR) was used
to inhibit canonical NF-B signaling as previously described (46,
47). Briefly, degradation of IB is required for nuclear localiza-
tion of NF-B canonical transcription factors. Mutation of serine
residues within IB prevents its degradation and inhibits NF-B
signaling (47). Moreover, the IB SR has specifically been shown
to be effective at preventing TRAF-mediated NF-B activation
(30, 46). A dominant negative TRAF6 construct was used to im-
pede TRAF6 function as described previously (5, 31). CTAR1 ac-
tivation of NF-B signaling was inhibited using a myc-tagged
dominant negative TRAF2 construct that has been described pre-
viously (5, 32). FLAG-HA-tagged LMP1 was transfected into cells
with and without the HA-tagged SR, myc-tagged dnTRAF2, or
dnTRAF6. The resulting lysates were probed for LMP1, IB,
Myc, and TRAF6 to verify that all constructs were expressed as
expected (Fig. 6E). Importantly, IB SR, dnTRAF2, and dn-
TRAF6 failed to influence the overall expression of IGF1R (Fig.
6E). Two days after transfection, cell lysates were immunoprecipi-
tated with anti-pTyr and probed with anti-IGF1R to specifically
detect pIGF1R. Expression of the SR and dnTRAF6 selectively
decreased the activation of IGF1R to levels equivalent to those for
the pBabe vector control, while dnTRAF2 did not decrease
pIGF1R levels relative to those for LMP1 (Fig. 6F). In agreement
with these data, qRT-PCR analysis indicated that the presence of
dnTRAF2 did not impact the ability of LMP1 to induce IGF1
mRNA relative to pBabe vector controls (Fig. 6G). In contrast, the
presence of the SR or dnTRAF6 inhibited IGF1 expression relative
to that in pBabe control cells (Fig. 6G). The expression of LMP1
with or without the SR, dnTRAF2, or dnTRAF6 did not alter the
transcription of IGF1R (Fig. 6G). In summary, these findings re-
veal that LMP1 activates the canonical NF-B pathway to increase
expression of IGF1 and activate IGF1R.
DISCUSSION
The transforming properties of LMP1 have been described in
multiple systems. It is thought that the effects of the LMP1 CTAR1
domain on EGFR expression are important components in alter-
ing epithelial cell growth. LMP1 increases EGFR expression
through an unusual form of NF-B signaling mediated by p50 and
BCL3 (10, 15–17). Similarly, NF-B signaling may also induce the
expression of the RTK RON (26, 27). Analysis of 293T cells trans-
fected with LMP1 or pBabe controls did not reveal differential
RON phosphorylation, but EGFR activation was enhanced, in
keeping with previous results (Fig. 1A to C). Interestingly, LMP1
selectively increased the phosphorylation of IGF1R, and this effect
was validated in multiple cell lines regardless of whether LMP1
FIG 5 LMP1 regulates IGF1R activation via ligand IGF1. (A) qRT-PCR was used to assess the expression of IGF1R, IGF1, and IGF2. (B) ELISAs measured the
secretion of IGF1. In panels A and B, the ratio of LMP1-positive cells relative to LMP1-negative cells is depicted. (C) LMP1-expressing 293T cell lysates were
immunoprecipitated with anti-pTyr and probed with anti-IGF1R to detect pIGF1R after treatment with control goat IgG (CTL IgG) or with neutralizing
anti-IGF1R (Ab) for 24 h. In parallel, total cell lysates (TCLs) were probed for IGF1R, LMP1, and GAPDH. (D) Proliferation of 293T or MCF10a (MCF) cells
when treated with neutralizing anti-IGF1R (Ab) or IgG control for 48 h. The fraction of treated cells relative to cells without treatment was calculated, and
proliferation of LMP1-positive cells was taken relative to that of LMP1-negative cells. All antibody concentrations are g/ml. *, the value for LMP1-positive cells
is significantly different than that for pBabe control cells (P  0.05).
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FIG 6 The CTAR2 domain of LMP1 controls IGF1 secretion and IGF1R activation via NF-B signaling. (A) Wild-type (WT) LMP1 as well as the A5 and 378
mutants of LMP1 were expressed in 293T cells. WT LMP1 has FLAG and HA tags, while LMP1 378 is missing a fragment of the C terminus; these alterations make
them slightly larger and smaller than the predicted 66-kDa LMP1, respectively. The protein expression of IGF1R was assessed in parallel. (B) 293T cells were
transfected with WT LMP1 or the indicated mutant. Lysates were immunoprecipitated with anti-pTyr and immunoblotted with anti-IGF1R to specifically detect
IGF1R phosphorylation. (C) qRT-PCR analyzing transcription of IGF1R and IGF1 with the indicated LMP1 constructs compared to pBabe controls. (D) ELISAs
measured secretion of IGF1 with the indicated LMP1 constructs compared to pBabe controls. (E) Immunoblots depicting 293T cells transfected with HA-tagged
LMP1 (66 kDa), Myc-tagged dominant negative TRAF2 (dnT2) (57 kDa), dominant negative TRAF6 (dnT6) (60 kDa), or HA-tagged IB superrepressor (SR)
(35 kDa). (F) Two days after transfection, the indicated cell lysates were immunoprecipitated with anti-pTyr and probed with anti-IGF1R to specifically detect
phospho-IGF1R. (G) qRT-PCR describing transcription of IGF1R and IGF1 with the indicated constructs. All results compare gene expression of LMP1-positive
cells to that of pBabe control cells. *, LMP1-expressing cells were significantly different from pBabe control cells (P  0.05). x, the indicated value is significantly
different from that for WT LMP1 (P  0.05).
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was transiently or stably expressed (Fig. 1C and D). EBV infects
both epithelial cells and B cells, and LMP1 may differentially reg-
ulate RTKs depending on the cellular context. For instance, LMP1
induces RON expression in B cells and NPC cells, while induction
of EGFR expression occurs primarily in epithelial cells (15–17, 26,
27). Previous analyses of lymphocytes suggested that EBV infec-
tion decreased the expression of IGF1R, yet the data presented in
this paper indicate that LMP1 increases IGF1R activation in fibro-
blasts and immortalized or transformed epithelial cells (48) (Fig.
1). These data suggest that LMP1 uses different mechanisms to
regulate IGF1R expression and activation in lymphocytes and in
epithelial cells. In addition to showing that LMP1 selectively acti-
vated IGF1R, these studies revealed that targeting IGF1R with
small-molecule inhibitors or with shRNA specifically impaired
the Akt phosphorylation, proliferation, and focus formation of
LMP1-positive cells (Fig. 2, 3C to E, and 4). In keeping with pre-
vious findings, PPP targeted IGF1R with an IC50 of approximately
50 nM (39). In this study, AG1024 targeted IGF1R with an IC50 of
roughly 20 M, which is higher than the IC50 of 7 M reported by
other groups. Nevertheless, the 20 M IC50 value observed for
IGF1R is still below the 57 M IC50 at which AG1024 inhibits IR,
indicating that AG1024 would maintain specificity for IGF1R at a
concentration of 20 M (40). It should be noted that AG 1024
targets IGF1R without influencing EGFR activation at concentra-
tions up to 70 M and PPP does not alter pEGFR levels at doses
below 1 M (49, 50). The concentrations of IGF1R inhibitors used
in this study would not directly affect EGFR activation, indicating
that the effects detected after treatment with AG1024 and PPP
reflect effects on IGF1R phosphorylation.
Since PPP, AG1024, and shRNA against IGF1R all generated
similar phenotypes in LMP1-expressing cells, it is likely that the
effects generated by the small-molecule inhibitors are specifically
due to inhibition of IGF1R (Fig. 2 to 4). Inhibiting IGF1R reduced
both proliferation and Akt activation in 293T, MCF10a, and Rat1
cells, indicating that LMP1 expression, rather than cell type, im-
poses a requirement for active IGF1R signaling (Fig. 2 to 4). Con-
stitutively active myr-Akt rescued the decreased proliferation de-
tected in LMP1-positive cells upon IGF1R inhibition, suggesting
that IGF1R-mediated phosphorylation of Akt is required for cell
growth (Fig. 3F and G). Interestingly, inhibiting IGF1R does not
impair the migratory effects induced by LMP1 expression in ro-
dent fibroblasts, suggesting that LMP1-mediated activation of
IGF1R primarily induces cell proliferation (Fig. 3A and B).
IGF1R activating mutations are rare, and to date, no such mu-
tations have been reported in cancer. In transformed cells, IGF1R
is frequently activated by overexpression or by alterations in li-
gand expression or secretion. Although both IGF1 and IGF2 tran-
scription may be altered, changes in IGF2 expression are more
frequently detected in cancer (51). LMP1 did not modify IGF1R
or IGF2 expression, but it did increase both the mRNA expression
and secretion of IGF1 by 1.5- to 2-fold (Fig. 5A and B). Treatment
with an anti-IGF1R designed to prevent ligand binding reduced
the activation of IGF1R and selectively decreased the proliferation
of LMP1-positive cells relative to vector control cells, thus rein-
forcing the finding that LMP1 regulates IGF1R activity in a ligand-
dependent manner (Fig. 5C and D). Interestingly, anti-IGF1R did
not reduce LMP1-positive cell proliferation as much as targeting
IGF1R with small-molecule inhibitors or shRNA (Fig. 2C and D,
4C, and 5D). It may be that anti-IGF1R does not decrease IGF1R
activation to the same extent as the other methodologies or that
there are other, as-yet-unidentified LMP1-dependent mecha-
nisms that promote IGF1R activation. It has been shown that the
EBV-encoded small RNAs (EBERs) can induce IGF1 secretion
(52). It is therefore possible that EBERs may cooperate with LMP1
to activate IGF1R during epithelial infection.
LMP1 has two signaling domains, CTAR1 and CTAR2, which
regulate a large portion of the signaling capabilities of LMP1. The
LMP1 378 mutation targeting CTAR2 selectively reduced the
mRNA expression and secretion of IGF1 relative to that for WT
LMP1 and the LMP1 A5 mutant targeting CTAR1 (Fig. 6C and D).
In keeping with these findings, LMP1 A5 did not alter IGF1R
phosphorylation relative to that for WT LMP1, while LMP1 378
reduced IGF1R phosphorylation to levels equivalent to those in
pBabe control cells (Fig. 6A and B). The CTAR2 domain of LMP1
is known to activate canonical NF-B signaling via TRAF6, and it
was hypothesized that both TRAF6 and NF-B were required for
LMP1 to increase IGF1 mRNA levels and IGF1R activation (9,
46, 47). Indeed, inhibition of NF-B with the IB SR and
inhibition of TRAF6 signaling with dnTRAF6 both reduced
IGF1R activation and IGF1 synthesis (Fig. 6E to G). The spec-
ificity of these observations was confirmed by the fact that ex-
pression of dnTRAF2 did not impact IGF1 mRNA expression
or pIGF1R levels (Fig. 6E to G). Interestingly, neither the SR
nor dnTRAF6 impacted the expression of IGF1R (Fig. 6G).
It has been shown that NPC tumors express both EGFR and
IGF1R, although it is not clear whether IGF1R expression is spe-
cifically upregulated in EBV-infected tumors (53–55). High ex-
pression of IGF1R has been correlated with poor NPC patient
survival, and targeting NPC xenografts with PPP reduces tumor
growth (53, 56). Additionally, preliminary data suggest that tar-
geting both EGFR and IGF1R in NPC may be more beneficial than
targeting either RTK individually (15, 57). The work described in
this paper reveals that LMP1 activates not only EGFR but also
IGF1R. These findings may provide the underlying mechanism
behind the effects described in the IGF1R-directed clinical studies.
Importantly, these clinical reports support the concept that IGF1R
is a viable therapeutic target in NPC patients and that targeting
both EGFR and IGF1R may be more beneficial than targeting
either RTK individually.
IGF1R is capable of interacting with other RTKs to promote
cross-phosphorylation and downstream signaling. Of note,
IGF1R can physically associate with EGFR, and the ligands EGF
and IGF1 can activate both EGFR and IGF1R even when the two
receptors are not physically connected (58–61). Since LMP1 reg-
ulates activation of EGFR and IGF1R, it is possible that LMP1
promotes interaction between these receptors to facilitate their
phosphorylation. Alternately, although it is known that LMP1 in-
creases EGFR phosphorylation, it is not yet known how this ele-
vated activation occurs. Perhaps the increased secretion of IGF1
induced by LMP1 is responsible for promoting EGFR phosphor-
ylation. To facilitate the use of EGFR and IGF1R as therapeutic
targets, it will be important to explore the potential interaction
and cross-phosphorylation between these two RTKs.
In summary, the data in this paper demonstrate that the
CTAR2 domain of LMP1 signals through the canonical NF-B
pathway to increase the mRNA expression and secretion of the
IGF1R ligand IGF1. The elevated secretion of IGF1 promotes the
phosphorylation of IGF1R, leading to the phosphorylation of Akt
and increased cell proliferation. Inhibition of IGF1R selectively
reduces the Akt phosphorylation, cell proliferation, and focus for-
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mation of LMP1-positive cells. These data describe a novel mech-
anism through which LMP1 promotes cellular transformation
and also identify a potential method to selectively target EBV-
positive, LMP1-expressing cells. Taken together, these findings
may yield improved therapeutics for the treatment of NPC.
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